Amgen's new meds beat estimates as anemia drugs slip

Amgen's ($AMGN) anemia drugs faltered again in the fourth quarter with sales declining 15% on Aranesp and 18% on Epogen. New bone drugs Xgeva and Prolia beat analyst estimates for their first full year on the market with $554 million in sales. Report